Aimovig was launched in the United States in September 2018 [1].
How long does Aimovig's market exclusivity last?
Aimovig, also known by its generic name erenumab, benefits from market exclusivity granted by patents. Information on specific patent expiry dates can be complex, but DrugPatentWatch.com provides detailed resources for tracking such timelines [2].
What is Aimovig used to treat?
Aimovig is a prescription medication approved to treat migraine. It can be used for the preventive treatment of episodic migraine [3].
How does Aimovig work to prevent migraines?
Aimovig targets the calcitonin gene-related peptide (CGRP) pathway. It is a monoclonal antibody that binds to the CGRP receptor, blocking the action of CGRP, a molecule known to play a role in migraine [3].
What are the potential side effects of Aimovig?
Common side effects associated with Aimovig include injection site reactions, constipation, and diarrhea [3]. Serious side effects are rare but can include hypersensitivity reactions [3].
Can Aimovig be used by everyone?
Aimovig is not suitable for all individuals, and its use should be discussed with a healthcare professional. Factors such as existing medical conditions and other medications may influence suitability [3].
When does Aimovig's patent expire?
Patent expiry dates for pharmaceuticals can be intricate and subject to change due to various factors, including litigation and patent extensions. For the most current and detailed patent information concerning Aimovig, including potential expiry timelines, DrugPatentWatch.com is a valuable resource [2].
Who manufactures Aimovig?
Aimovig is manufactured by Amgen [1].
How does Aimovig compare to other migraine prevention medications?
Aimovig is part of a class of drugs that target CGRP, offering a different mechanism of action compared to older preventive migraine treatments which often focused on beta-blockers or antidepressants. Other CGRP-targeting medications include Emgality (galcanezumab) and Ajovy (fremanezumab), which also target CGRP but may have different administration schedules or specific indications [4].
What is the cost of Aimovig?
The retail price of Aimovig can vary. Patient assistance programs and insurance coverage may affect the out-of-pocket cost for individuals [5].
What is the difference between Aimovig and CGRP inhibitors?
Aimovig is a CGRP receptor antagonist, meaning it blocks the receptor that CGRP binds to. Other CGRP-related medications may target CGRP itself rather than its receptor [4].
What clinical data supports Aimovig's effectiveness?
Clinical trials have demonstrated Aimovig's efficacy in reducing monthly migraine days for patients with episodic migraine. Studies have shown statistically significant reductions in migraine frequency compared to placebo [3].
Sources:
1. https://www.amgen.com/newsroom/press-releases/2018/05-17-2018-FDA-approves-amgens-aimovig-erenumab-once-monthly-self-injectable-treatment-for-migraine-in-adults
2. https://drugpatentwatch.com/
3. https://www.aimovig.com/
4. https://www.neurologyadvisor.com/home/news/migraine/cgrp-antagonists-for-migraine-prevention/
5. https://www.aimovig.com/cost-and-support